180477-68-3

Basic information

• Product Name: (4-(benzyloxy)but-1-ene-1,1-diyl)dibenzene
• Synonyms: (4-(benzyloxy)but-1-ene-1,1-diyl)dibenzene
• CAS NO: 180477-68-3
• Molecular Weight: 314.427
• Mol File: 180477-68-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (4-(benzyloxy)but-1-ene-1,1-diyl)dibenzene(CAS DataBase Reference)
• NIST Chemistry Reference: (4-(benzyloxy)but-1-ene-1,1-diyl)dibenzene(180477-68-3)
• EPA Substance Registry System: (4-(benzyloxy)but-1-ene-1,1-diyl)dibenzene(180477-68-3)

Safety Data

• Hazardous Substances Data: 180477-68-3(Hazardous Substances Data)

Upstream product

• 1462-37-9 bromoethyl-2-benzyl ether 
• 26189-62-8 phenyl 2,2-diphenylethenyl sulfone 
• 100-39-0 benzyl bromide 
• 93903-27-6 benzyl 4-(benzyloxy)butanoate 
• 119-61-9 benzophenone 
• 54314-85-1 (3-benzyloxypropyl)triphenylphosphonium bromide 

Downstream Products

• 56740-71-7 4,4-diphenyl-1-butanol 
• 251359-78-1 VUF 5667 
• 104675-46-9 4-methanesulfonyloxy-1,1-diphenylbutane 

Relevant articles and documents

Alkenylation of unactivated alkyl bromides through visible light photocatalysis

Two visible-light driven alkenylation reactions of unactivated alkyl bromides, which were enabled by the use of Ir(dF(CF3)ppy)2(dtbbpy)PF6 as the photocatalyst and (TMS)3SiH as the atom transfer reagent to activate the alkyl bromides, were described for the first time. These protocols can be used to produce a variety of alkenes from easily available feedstock with good reaction efficiency and high chemoselectivity under mild reaction conditions. To further demonstrate the applicability of the present strategy, the alkenylation of bioactive molecules and glycosyl bromides, as well as the alkynylation of unactivated alkyl bromides, was proven to be feasible.

Discovery of novel non-peptide CCR1 receptor antagonists

Ligands for the CCR1 receptor (MIP-1α and RANTES) have been implicated in a number of chronic inflammatory diseases, most notably multiple sclerosis and rheumatoid arthritis. Because these ligands share a common receptor, CCR1, we sought to discover antagonists for this receptor as an approach to treating these disorders. A novel series of 4-hydroxypiperidines has been discovered by high throughput screening (HTS) which potently inhibits the binding of MIP-1α and RANTES to the recombinant human CCR1 chemokine receptor. The structure-activity relationships of various segments of this template are described as the initial HTS lead 1 was optimized synthetically to the highly potent receptor antagonist 6s. This compound has been shown to have at least 200-fold selectivity for inhibition of CCR1 over other human 7- TM receptors, including other chemokine receptors. In addition, data obtained from in vitro functional assays demonstrate the functional antagonism of compound 6s and structurally related analogues against the CCR1 receptor in a concentration dependent manner. The discovery and optimization of potent and selective CCR1 receptor antagonists represented by compound 6s potentially represent a novel approach to the treatment of chronic inflammatory diseases.